Pregabalin Capsule
Product Images NDC 71335-1740

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351740)

Label for Pregabalin 100 mg capsule by Bryant Ranch Prepack. The orange capsule is identified with code A010 and PREG100. The label states it is comparable to Lyrica 100 mg capsules by Alkem Laboratories Limited. It includes storage instructions at 20°-25°C (68°-77°F) and a caution to keep out of reach of children. The label shows quantities of 30 capsules and features an NDC number 71335-1740-1.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula panel displaying the equation for calculating creatinine clearance (CLCr) using age, weight, and serum creatinine level, including a notation to multiply by 0.85 for female patients.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart comparing responder rates (%) in two clinical studies, Study E1 and Study E3, for different dosages of pregabalin versus placebo. Study E1 shows increasing response rates from placebo to 600 mg/day dosages administered twice daily (BID), while Study E3 compares placebo, 600 mg/day BID, and 600 mg/day three times daily (TID). Sample sizes for each group are noted below the bars with statistically significant results marked by asterisks.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing seizure reduction as median percent change from baseline versus pregabalin dose (mg/day). The graph compares four studies with different dosing schedules: Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID. Data points include significant p-values, highlighting the relationship between increasing pregabalin doses and seizure reduction.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and placebo, illustrating higher patient improvement percentages at increasing pain improvement levels for higher Pregabalin dosages compared to placebo.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph depicting the percent of subjects improved over various percent improvements from baseline to Week 12 BOCF. The graph compares two groups, Pregabalin and Placebo, with distinct lines representing each group's response over the percent improvement scale ranging from 0 to 100.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16, for Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to Week 16 BOCF, and the y-axis shows the percent of subjects improved. Two lines represent Pregabalin (solid) and Placebo (dashed), with Pregabalin showing consistently higher improvement.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percent of patients improved relative to percent improvement in pain from baseline. The graph compares two groups: patients treated with Pregabalin 100 mg three times a day and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents percent of patients improved.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing percent of patients improved over time, comparing different doses of Pregabalin (75 mg, 150 mg, and 300 mg taken twice a day) against placebo. The x-axis represents time in hours, and the y-axis represents the percentage of patients reporting improvement from pain baseline.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo, showing their response distribution across varying pain improvement percentages.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. Three curves compare pregabalin 100 mg three times a day, pregabalin 50 mg three times a day, and placebo, illustrating patient response to different doses of pregabalin versus placebo.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing the percent of patients improved (y-axis) versus percent improvement in pain from baseline (x-axis) for pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. Four curves compare patient response across these dosages, with higher doses generally showing higher improvement percentages.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve graph comparing the percentage of subjects without LTR (loss to response) over 180 days between Pregabalin and placebo groups. The vertical axis shows estimated percentage of subjects without LTR, and the horizontal axis represents time in days. The solid line corresponds to Pregabalin, and the dashed line to placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin showing its molecular framework, including functional groups such as an amino group (NH2) and a carboxylic acid group (CO2H). The image depicts bonds and stereochemistry relevant to this active pharmaceutical ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.